CSNK1E — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL30702	1.00	20/20
SCHEMBL30737	1.00	20/20
SCHEMBL31187	1.00	20/20
SCHEMBL31214	1.00	20/20
SCHEMBL31219	1.00	20/20
SCHEMBL31230	1.00	20/20
SCHEMBL31265	1.00	20/20
SCHEMBL31341	1.00	20/20
SCHEMBL31361	1.00	20/20
SCHEMBL31429	1.00	20/20
SCHEMBL31441	1.00	20/20
SCHEMBL31480	1.00	20/20
SCHEMBL30724	0.80	20/20
SCHEMBL31425	0.77	20/20
SCHEMBL31201	0.76	20/20
SCHEMBL31321	0.75	20/20
SCHEMBL30709	0.75	20/20
SCHEMBL31260	0.74	20/20
SCHEMBL31216	0.74	20/20
SCHEMBL31427	0.72	20/20

Clinical trials — most relevant to CSNK1E by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients	PHASE3	ACTIVE_NOT_RECRUITING
Mitochondrial Oxidation and Insulin Resistance in Burn Patients Treated With Fenofibrate	PHASE2/PHASE3	WITHDRAWN
Doxycycline in Human Pulmonary Tuberculosis	PHASE2	COMPLETED
Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor	PHASE2	RECRUITING
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma	PHASE1/PHASE2	COMPLETED
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Nilotinib in Huntington's Disease	PHASE1	UNKNOWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma	PHASE1	COMPLETED
Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer	EARLY_PHASE1	COMPLETED
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
Ischemic Preconditioning - Perspectives of Use Vivio/in Vitro Studies	nan	ENROLLING_BY_INVITATION
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients	nan	UNKNOWN
Nuclear Myosin VI - a Therapeutic Target in Breast Cancer	nan	UNKNOWN
Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex	nan	COMPLETED
Study of Metabolic Modifications in Children With Noonan Syndrome	nan	COMPLETED
Improving the Diagnosis of Common Variable Immune Deficiency	nan	COMPLETED
Integrated Proteomic HPLC-ESI-MS Analysis of Salivary Peptides of Preterm Newborns: a Pilot Study	nan	COMPLETED
Genetic Analysis of Gray Platelet Syndrome	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults	nan	COMPLETED
Signs and Symptoms of Genetic Abnormalities Linked to Inherited Heart Disease	nan	COMPLETED
Characterization of New Candidate Genes in Cases of Human Inherited Thrombocytopenia (CATCH)	nan	COMPLETED
Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population	nan	COMPLETED
Signs and Symptoms Associated With Molecular Defects in Genetically Inherited Heart Disease	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CSNK1E binder may also engage these)

Protein	Name	Similarity
Q5ZLL1	—	1.000	Q5ZLL1 →
Q5RC72	—	1.000	Q5RC72 →
Q6P3K7	—	1.000	Q6P3K7 →
Q06486	—	1.000	Q06486 →
Q7T2E3	—	1.000	Q7T2E3 →
CSNK1D	Casein kinase I isoform delta	1.000	landscape →
P35508	—	1.000	P35508 →
Q6P647	—	1.000	Q6P647 →
Q9DC28	—	1.000	Q9DC28 →
Q5BP74	—	1.000	Q5BP74 →
Q9JMK2	—	1.000	Q9JMK2 →
Q39050	—	0.995	Q39050 →
A0A0E0S0W9	—	0.993	A0A0E0S0W9 →
Q9ZUP4	—	0.992	Q9ZUP4 →
P42158	—	0.992	P42158 →
Q62762	—	0.991	Q62762 →
Q62761	—	0.991	Q62761 →
Q8BVP5	—	0.990	Q8BVP5 →
Q8VYK9	—	0.990	Q8VYK9 →
Q93Z18	—	0.990	Q93Z18 →
CSNK1G2	Casein kinase I isoform gamma-2	0.989	landscape →
Q5PRD4	—	0.988	Q5PRD4 →
G5EI58	—	0.988	G5EI58 →
Q8BTH8	—	0.987	Q8BTH8 →
Q5ZJS0	—	0.987	Q5ZJS0 →
Q9LSX4	—	0.987	Q9LSX4 →
Q9ZWB3	—	0.987	Q9ZWB3 →
Q4R9A9	—	0.987	Q4R9A9 →
Q6NRT0	—	0.986	Q6NRT0 →
CSNK1G1	Casein kinase I isoform gamma-1	0.986	landscape →